Super-ADCs
for Safer Cancer Therapies

At BioLoomics, we engineer Antibody Drug Conjugates (ADCs) with peptides that enhance payload delivery beyond the limitations of traditional ADCs

Super-ADCs

We add membrane binding peptides to the antibody component of ADCs. This innovation enhances membrane loading and internalization to increase payload release
Learn More

Therapeutic Programs

Where traditional ADCs have fallen short, we aim to deliver best-in-class therapeutics against clinically validated targets in oncology
Learn More

Directed Evolution

We leverage advanced bioinformatics and AI to create libraries of millions of peptide designs that are each tested using our high throughput wet-lab process. This discovery engine optimizes ADCs for membrane loading, internalization, and target specific cytotoxicity
Learn More

About Us

Removing the Boundaries of Traditional ADCs

We are passionate team on a mission to unlock the full potential of ADCs to improve the lives of patients
Meet Our Team

Latest News

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Jun 13, 2024

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs

January 29, 2025
View News Article